Annual Net Income
$3.95 B
-$384.80 M-8.87%
31 December 2023
Summary:
Regeneron Pharmaceuticals annual net profit is currently $3.95 billion, with the most recent change of -$384.80 million (-8.87%) on 31 December 2023. During the last 3 years, it has fallen by -$4.12 billion (-51.04%). REGN annual net income is now -51.04% below its all-time high of $8.08 billion, reached on 31 December 2021.REGN Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Net Income
$1.34 B
-$91.70 M-6.40%
30 September 2024
Summary:
Regeneron Pharmaceuticals quarterly net profit is currently $1.34 billion, with the most recent change of -$91.70 million (-6.40%) on 30 September 2024. Over the past year, it has increased by +$181.00 million (+15.61%). REGN quarterly net income is now -56.74% below its all-time high of $3.10 billion, reached on 30 June 2021.REGN Quarterly Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM Net Income
$4.65 B
+$332.80 M+7.70%
30 September 2024
Summary:
Regeneron Pharmaceuticals TTM net profit is currently $4.65 billion, with the most recent change of +$332.80 million (+7.70%) on 30 September 2024. Over the past year, it has increased by +$700.90 million (+17.73%). REGN TTM net income is now -42.36% below its all-time high of $8.08 billion, reached on 31 December 2021.REGN TTM Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
REGN Net Income Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | +15.6% | +17.7% |
| 3 y3 years | -51.0% | -39.9% | -42.4% |
| 5 y5 years | +86.9% | +69.3% | +120.0% |
REGN Net Income High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -51.0% | +12.5% | -39.9% | +85.7% | -42.4% | +20.6% |
| 5 y | 5 years | -51.0% | +86.9% | -56.7% | +114.6% | -42.4% | +120.0% |
| alltime | all time | -51.0% | +1882.8% | -56.7% | +2244.8% | -42.4% | +2198.9% |
Regeneron Pharmaceuticals Net Income History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $1.34 B(-6.4%) | $4.65 B(+7.7%) |
| June 2024 | - | $1.43 B(+98.4%) | $4.32 B(+12.0%) |
| Mar 2024 | - | $722.00 M(-37.7%) | $3.86 B(-2.4%) |
| Dec 2023 | $3.95 B(-8.9%) | $1.16 B(+15.1%) | $3.95 B(-0.9%) |
| Sept 2023 | - | $1.01 B(+4.1%) | $3.99 B(-7.2%) |
| June 2023 | - | $968.40 M(+18.4%) | $4.30 B(+2.8%) |
| Mar 2023 | - | $817.80 M(-31.7%) | $4.18 B(-3.6%) |
| Dec 2022 | $4.34 B(-46.3%) | $1.20 B(-9.0%) | $4.34 B(-19.2%) |
| Sept 2022 | - | $1.32 B(+54.4%) | $5.37 B(-5.6%) |
| June 2022 | - | $852.10 M(-12.5%) | $5.69 B(-28.3%) |
| Mar 2022 | - | $973.50 M(-56.3%) | $7.93 B(-1.8%) |
| Dec 2021 | $8.08 B(+129.9%) | $2.23 B(+36.6%) | $8.08 B(+15.4%) |
| Sept 2021 | - | $1.63 B(-47.3%) | $7.00 B(+12.7%) |
| June 2021 | - | $3.10 B(+177.9%) | $6.21 B(+55.0%) |
| Mar 2021 | - | $1.12 B(-3.0%) | $4.00 B(+14.0%) |
| Dec 2020 | $3.51 B(+66.0%) | $1.15 B(+36.5%) | $3.51 B(+11.3%) |
| Sept 2020 | - | $842.10 M(-6.2%) | $3.16 B(+5.8%) |
| June 2020 | - | $897.30 M(+43.7%) | $2.98 B(+30.9%) |
| Mar 2020 | - | $624.60 M(-21.1%) | $2.28 B(+7.7%) |
| Dec 2019 | $2.12 B(-13.4%) | $792.00 M(+18.3%) | $2.12 B(-1.3%) |
| Sept 2019 | - | $669.60 M(+246.8%) | $2.14 B(+3.6%) |
| June 2019 | - | $193.10 M(-58.1%) | $2.07 B(-14.8%) |
| Mar 2019 | - | $461.10 M(-43.8%) | $2.43 B(-0.7%) |
| Dec 2018 | $2.44 B(+104.0%) | $820.40 M(+38.0%) | $2.44 B(+36.0%) |
| Sept 2018 | - | $594.70 M(+7.9%) | $1.80 B(+13.0%) |
| June 2018 | - | $551.40 M(+15.4%) | $1.59 B(+11.5%) |
| Mar 2018 | - | $478.00 M(+175.5%) | $1.43 B(+19.1%) |
| Dec 2017 | $1.20 B(+33.8%) | $173.51 M(-55.3%) | $1.20 B(-6.2%) |
| Sept 2017 | - | $388.32 M(+0.1%) | $1.28 B(+10.7%) |
| June 2017 | - | $387.74 M(+55.8%) | $1.15 B(+19.9%) |
| Mar 2017 | - | $248.93 M(-1.6%) | $963.05 M(+7.5%) |
| Dec 2016 | $895.50 M(+40.8%) | $253.09 M(-4.4%) | $895.50 M(+12.3%) |
| Sept 2016 | - | $264.80 M(+35.0%) | $797.40 M(+7.3%) |
| June 2016 | - | $196.22 M(+8.2%) | $743.00 M(+0.2%) |
| Mar 2016 | - | $181.38 M(+17.0%) | $741.42 M(+16.6%) |
| Dec 2015 | $636.06 M(+88.1%) | $154.99 M(-26.3%) | $636.06 M(+11.4%) |
| Sept 2015 | - | $210.40 M(+8.1%) | $571.16 M(+28.6%) |
| June 2015 | - | $194.64 M(+156.0%) | $444.13 M(+28.4%) |
| Mar 2015 | - | $76.02 M(-15.6%) | $345.84 M(+2.3%) |
| Dec 2014 | $338.13 M(-18.3%) | $90.09 M(+8.1%) | $338.13 M(+1.2%) |
| Sept 2014 | - | $83.38 M(-13.5%) | $334.21 M(-14.8%) |
| June 2014 | - | $96.35 M(+41.1%) | $392.14 M(+2.3%) |
| Mar 2014 | - | $68.31 M(-20.7%) | $383.17 M(-7.4%) |
| Dec 2013 | $413.74 M(-44.9%) | $86.18 M(-39.0%) | $413.74 M(-48.2%) |
| Sept 2013 | - | $141.31 M(+61.7%) | $797.96 M(-5.9%) |
| June 2013 | - | $87.38 M(-11.6%) | $848.13 M(+1.3%) |
| Mar 2013 | - | $98.87 M(-79.0%) | $837.49 M(+11.6%) |
| Dec 2012 | $750.27 M(-438.3%) | $470.41 M(+145.7%) | $750.27 M(+231.4%) |
| Sept 2012 | - | $191.47 M(+149.5%) | $226.42 M(-925.9%) |
| June 2012 | - | $76.74 M(+558.7%) | -$27.41 M(-83.6%) |
| Mar 2012 | - | $11.65 M(-121.8%) | -$166.66 M(-24.8%) |
| Dec 2011 | -$221.76 M(+112.3%) | -$53.44 M(-14.3%) | -$221.76 M(+21.2%) |
| Sept 2011 | - | -$62.37 M(-0.2%) | -$182.91 M(+18.4%) |
| June 2011 | - | -$62.51 M(+43.9%) | -$154.42 M(+31.5%) |
| Mar 2011 | - | -$43.45 M(+197.6%) | -$117.39 M(+12.4%) |
| Dec 2010 | -$104.47 M(+54.0%) | -$14.60 M(-56.9%) | -$104.47 M(-17.3%) |
| Sept 2010 | - | -$33.88 M(+33.0%) | -$126.36 M(+35.1%) |
| June 2010 | - | -$25.47 M(-16.5%) | -$93.50 M(+12.7%) |
| Mar 2010 | - | -$30.52 M(-16.4%) | -$82.96 M(+22.3%) |
| Dec 2009 | -$67.83 M(-14.3%) | -$36.49 M(+3495.0%) | -$67.83 M(+14.4%) |
| Sept 2009 | - | -$1.01 M(-93.2%) | -$59.28 M(-25.3%) |
| June 2009 | - | -$14.94 M(-2.9%) | -$79.38 M(-4.5%) |
| Mar 2009 | - | -$15.39 M(-44.9%) | -$83.13 M(+4.8%) |
| Dec 2008 | -$79.13 M(-25.1%) | -$27.94 M(+32.3%) | -$79.36 M(+23.1%) |
| Sept 2008 | - | -$21.11 M(+13.0%) | -$64.49 M(-18.6%) |
| June 2008 | - | -$18.69 M(+60.9%) | -$79.22 M(-9.3%) |
| Mar 2008 | - | -$11.62 M(-11.1%) | -$87.30 M(-17.3%) |
| Dec 2007 | -$105.60 M | -$13.07 M(-63.5%) | -$105.60 M(-14.5%) |
| Sept 2007 | - | -$35.84 M(+33.9%) | -$123.50 M(+7.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2007 | - | -$26.77 M(-10.5%) | -$115.07 M(+2.9%) |
| Mar 2007 | - | -$29.92 M(-3.4%) | -$111.87 M(+9.3%) |
| Dec 2006 | -$102.34 M(+7.2%) | -$30.97 M(+13.0%) | -$102.34 M(+1.3%) |
| Sept 2006 | - | -$27.41 M(+16.3%) | -$101.04 M(-6.7%) |
| June 2006 | - | -$23.58 M(+15.7%) | -$108.28 M(-3.1%) |
| Mar 2006 | - | -$20.38 M(-31.3%) | -$111.70 M(+17.0%) |
| Dec 2005 | -$95.45 M(-328.9%) | -$29.67 M(-14.4%) | -$95.45 M(+51.5%) |
| Sept 2005 | - | -$34.65 M(+28.3%) | -$62.98 M(+59.8%) |
| June 2005 | - | -$27.00 M(+554.8%) | -$39.41 M(+46.2%) |
| Mar 2005 | - | -$4.12 M(-247.7%) | -$26.96 M(-164.6%) |
| Dec 2004 | $41.70 M(-138.8%) | $2.79 M(-125.2%) | $41.70 M(+113.5%) |
| Sept 2004 | - | -$11.08 M(-23.9%) | $19.53 M(+509.2%) |
| June 2004 | - | -$14.55 M(-122.5%) | $3.21 M(-125.4%) |
| Mar 2004 | - | $64.53 M(-433.0%) | -$12.61 M(-88.2%) |
| Dec 2003 | -$107.46 M(-13.6%) | -$19.38 M(-29.3%) | -$107.25 M(-13.2%) |
| Sept 2003 | - | -$27.40 M(-9.7%) | -$123.56 M(-4.2%) |
| June 2003 | - | -$30.36 M(+0.8%) | -$128.98 M(-0.0%) |
| Mar 2003 | - | -$30.11 M(-15.6%) | -$129.04 M(+3.8%) |
| Dec 2002 | -$124.38 M(+63.3%) | -$35.69 M(+8.8%) | -$124.38 M(+6.2%) |
| Sept 2002 | - | -$32.82 M(+7.9%) | -$117.06 M(+12.4%) |
| June 2002 | - | -$30.42 M(+19.6%) | -$104.18 M(+17.6%) |
| Mar 2002 | - | -$25.45 M(-10.3%) | -$88.59 M(+16.3%) |
| Dec 2001 | -$76.18 M(+228.1%) | -$28.38 M(+42.4%) | -$76.18 M(+35.4%) |
| Sept 2001 | - | -$19.93 M(+34.4%) | -$56.26 M(+42.6%) |
| June 2001 | - | -$14.83 M(+13.8%) | -$39.44 M(+43.6%) |
| Mar 2001 | - | -$13.04 M(+54.2%) | -$27.46 M(+26.3%) |
| Dec 2000 | -$23.21 M(+0.5%) | -$8.46 M(+171.2%) | -$21.75 M(+48.0%) |
| Sept 2000 | - | -$3.12 M(+9.3%) | -$14.69 M(-10.8%) |
| June 2000 | - | -$2.85 M(-61.0%) | -$16.47 M(-23.1%) |
| Mar 2000 | - | -$7.32 M(+422.7%) | -$21.42 M(-6.9%) |
| Dec 1999 | -$23.10 M(+168.6%) | -$1.40 M(-71.4%) | -$23.00 M(-15.1%) |
| Sept 1999 | - | -$4.90 M(-37.2%) | -$27.10 M(+14.8%) |
| June 1999 | - | -$7.80 M(-12.4%) | -$23.60 M(+72.3%) |
| Mar 1999 | - | -$8.90 M(+61.8%) | -$13.70 M(+59.3%) |
| Dec 1998 | -$8.60 M(-25.9%) | -$5.50 M(+292.9%) | -$8.60 M(+230.8%) |
| Sept 1998 | - | -$1.40 M(-166.7%) | -$2.60 M(-16.1%) |
| June 1998 | - | $2.10 M(-155.3%) | -$3.10 M(-67.4%) |
| Mar 1998 | - | -$3.80 M(-860.0%) | -$9.50 M(-18.1%) |
| Dec 1997 | -$11.60 M(-64.2%) | $500.00 K(-126.3%) | -$11.60 M(-42.6%) |
| Sept 1997 | - | -$1.90 M(-55.8%) | -$20.20 M(-25.7%) |
| June 1997 | - | -$4.30 M(-27.1%) | -$27.20 M(-10.8%) |
| Mar 1997 | - | -$5.90 M(-27.2%) | -$30.50 M(-5.9%) |
| Dec 1996 | -$32.40 M(+37.9%) | -$8.10 M(-9.0%) | -$32.40 M(+0.9%) |
| Sept 1996 | - | -$8.90 M(+17.1%) | -$32.10 M(+5.9%) |
| June 1996 | - | -$7.60 M(-2.6%) | -$30.30 M(+11.8%) |
| Mar 1996 | - | -$7.80 M(0.0%) | -$27.10 M(+15.3%) |
| Dec 1995 | -$23.50 M(-23.5%) | -$7.80 M(+9.9%) | -$23.50 M(+9.3%) |
| Sept 1995 | - | -$7.10 M(+61.4%) | -$21.50 M(+16.8%) |
| June 1995 | - | -$4.40 M(+4.8%) | -$18.40 M(-24.0%) |
| Mar 1995 | - | -$4.20 M(-27.6%) | -$24.20 M(-21.2%) |
| Dec 1994 | -$30.70 M(-23.1%) | -$5.80 M(+45.0%) | -$30.70 M(-15.7%) |
| Sept 1994 | - | -$4.00 M(-60.8%) | -$36.40 M(-13.3%) |
| June 1994 | - | -$10.20 M(-4.7%) | -$42.00 M(+1.9%) |
| Mar 1994 | - | -$10.70 M(-7.0%) | -$41.20 M(+3.5%) |
| Dec 1993 | -$39.90 M(+108.9%) | -$11.50 M(+19.8%) | -$39.80 M(+14.7%) |
| Sept 1993 | - | -$9.60 M(+2.1%) | -$34.70 M(+12.3%) |
| June 1993 | - | -$9.40 M(+1.1%) | -$30.90 M(+22.6%) |
| Mar 1993 | - | -$9.30 M(+45.3%) | -$25.20 M(+31.3%) |
| Dec 1992 | -$19.10 M(+324.4%) | -$6.40 M(+10.3%) | -$19.20 M(+28.9%) |
| Sept 1992 | - | -$5.80 M(+56.8%) | -$14.90 M(+49.0%) |
| June 1992 | - | -$3.70 M(+12.1%) | -$10.00 M(+51.5%) |
| Mar 1992 | - | -$3.30 M(+57.1%) | -$6.60 M(+50.0%) |
| Dec 1991 | -$4.50 M(+36.4%) | -$2.10 M(+133.3%) | -$4.40 M(+37.5%) |
| Sept 1991 | - | -$900.00 K(+200.0%) | -$3.20 M(+3.2%) |
| June 1991 | - | -$300.00 K(-72.7%) | -$3.10 M(-13.9%) |
| Mar 1991 | - | -$1.10 M(+22.2%) | -$3.60 M(+9.1%) |
| Dec 1990 | -$3.30 M | -$900.00 K(+12.5%) | -$3.30 M(+37.5%) |
| Sept 1990 | - | -$800.00 K(0.0%) | -$2.40 M(+50.0%) |
| June 1990 | - | -$800.00 K(0.0%) | -$1.60 M(+100.0%) |
| Mar 1990 | - | -$800.00 K | -$800.00 K |
FAQ
- What is Regeneron Pharmaceuticals annual net profit?
- What is the all time high annual net income for Regeneron Pharmaceuticals?
- What is Regeneron Pharmaceuticals quarterly net profit?
- What is the all time high quarterly net income for Regeneron Pharmaceuticals?
- What is Regeneron Pharmaceuticals quarterly net income year-on-year change?
- What is Regeneron Pharmaceuticals TTM net profit?
- What is the all time high TTM net income for Regeneron Pharmaceuticals?
- What is Regeneron Pharmaceuticals TTM net income year-on-year change?
What is Regeneron Pharmaceuticals annual net profit?
The current annual net income of REGN is $3.95 B
What is the all time high annual net income for Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals all-time high annual net profit is $8.08 B
What is Regeneron Pharmaceuticals quarterly net profit?
The current quarterly net income of REGN is $1.34 B
What is the all time high quarterly net income for Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals all-time high quarterly net profit is $3.10 B
What is Regeneron Pharmaceuticals quarterly net income year-on-year change?
Over the past year, REGN quarterly net profit has changed by +$181.00 M (+15.61%)
What is Regeneron Pharmaceuticals TTM net profit?
The current TTM net income of REGN is $4.65 B
What is the all time high TTM net income for Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals all-time high TTM net profit is $8.08 B
What is Regeneron Pharmaceuticals TTM net income year-on-year change?
Over the past year, REGN TTM net profit has changed by +$700.90 M (+17.73%)